Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsİbrahim Halil Şahin(University of Pittsburgh), Christina Wu(Mayo Clinic Hospital)British Journal of CancerOctober 13, 201910.1038/s41416-019-0599-yCited by 409SaveCiteExport RISWatch citationsRelated PapersTucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study|The Lancet Oncology|2023|244288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431)|Annals of Oncology|2025|0